Intrinsic subtypes and role of prognostic tests
Challenging the definition of intrinsic subtypes
HER2 low
HER2 mutations
HER3
TNBC
Potential of liquid biopsy
Biomarkers with therapeutic relevance
Target | Setting | Therapeutic agent |
---|---|---|
Germline mBCRA1/2 | Adjuvant, palliative | PARP inhibitors |
HER2 | Neoadjuvant, adjuvant, palliative | Trastuzumab, pertuzumab, neratinib, lapatinib, tucatinib, T‑DM1, T‑Dx |
HER2 mutations | Palliative | Neratinib, lapatinib, tucatinib |
HER2 low/HER2 heterogeneity | In development palliative | T‑Dx |
HR | Neoadjuvant, adjuvant, palliative | SERM, AI |
PIK3CA | Palliative | Alpelisib |
PD-L1/CPS | Palliative, neoadjuvant? | Atezolizumab, pembrolizumab |
PTEN, AKT | Palliative? | AKT inhibitors? |
TROP2? | Palliative | Sacituzumab–govitecan |